Drug intelligence / Profile preview

SC004 + SCAB1

Development stage: Preclinical
Lead developer: SCIINV Biosciences
Modality: Small Molecules
Administration: Oral

Overview

SC004 + SCAB1 is an oral fixed-dose combination therapy being developed by SCIINV Biosciences for the treatment of antimicrobial-resistant (AMR) infections. The drug candidate was discovered and optimized using SCIINV's proprietary Gen AI-based drug discovery platform, AMRx®, which integrates in silico modeling with in vitro and in vivo validation. As a combination of two small molecule components, SC004 and SCAB1, the therapy is designed to overcome existing resistance mechanisms in pathogens. While specific biological targets have not been disclosed, the program is part of a pipeline focused on addressing critical gaps in the global antimicrobial therapeutic landscape.

Other names: SC004 + SCAB1 (fixed dose combination)

Beyond the preview

Go deeper on SC004 + SCAB1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC004 + SCAB1.

Explore the full profile